Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324564 | 0.90 | ALDH1A1 (0.49) | MAPTKMT2ANPC1TSHRLMNA | |
| SCHEMBL6328370 | 0.88 | KMT2A (0.48) | MAPTKMT2ATP53NPC1TSHR | |
| SCHEMBL6326079 | 0.80 | HCAR2 (0.41) | MAPTKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL6328629 | 0.76 | HDAC1 (0.49) | MAPTKMT2ATP53NPC1TSHR | |
| SCHEMBL6328554 | 0.76 | HDAC1 (0.53) | MAPTKMT2ATP53TSHRLMNA | |
| SCHEMBL6333028 | 0.75 | HPGD (0.51) | MAPTKMT2ATP53NPC1TSHR | |
| SCHEMBL6325574 | 0.75 | TSHR (0.58) | MAPTTP53TSHRLMNACYP1A2 | |
| SCHEMBL6325569 | 0.75 | HDAC1 (0.49) | MAPTKMT2ATP53NPC1TSHR | |
| SCHEMBL6333150 | 0.74 | TP53 (0.50) | MAPTTP53TSHRLMNASMN1; SMN2 | |
| SCHEMBL6328500 | 0.74 | GAA (0.54) | MAPTTP53TSHRLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | MAPT 1336/4885KMT2A 3002/4885TP53 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.